Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

NCT00307086 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Plasma Cell Leukemia

Interventions

DRUG: Bortezomib
DRUG: Melphalan
PROCEDURE: PBSCT

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]